Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Chairman of the Board of Directors Sandford D. Smith is scheduled to present on Thursday, January 14, 2016 at 8:00 a.m. PST (11:00 a.m. EST). Mr. Smith will also introduce Aegerion’s newly appointed Chief Executive Officer, Mary Szela.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
